Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-Current Debt (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Non-Current Debt for 10 consecutive years, with $37.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 0.96% to $37.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.1 million through Dec 2025, up 0.96% year-over-year, with the annual reading at $37.1 million for FY2025, 0.96% up from the prior year.
  • Non-Current Debt hit $37.1 million in Q4 2025 for Coherus Oncology, roughly flat from $37.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $246.5 million in Q4 2023 to a low of $36.5 million in Q2 2024.
  • Historically, Non-Current Debt has averaged $123.4 million across 5 years, with a median of $73.6 million in 2021.
  • Biggest five-year swings in Non-Current Debt: soared 323.39% in 2022 and later tumbled 85.14% in 2024.
  • Year by year, Non-Current Debt stood at $75.5 million in 2021, then surged by 225.09% to $245.5 million in 2022, then grew by 0.41% to $246.5 million in 2023, then tumbled by 85.11% to $36.7 million in 2024, then rose by 0.96% to $37.1 million in 2025.
  • Business Quant data shows Non-Current Debt for CHRS at $37.1 million in Q4 2025, $37.0 million in Q3 2025, and $36.9 million in Q2 2025.